Cushings Syndrome (CS) is the result of a prolonged and inappropriate high exposition to free serum glucocorticoids. It comprises a series of signs and symptoms proper of the prolonged effect of the glucocorticoids. The clinical presentation may vary depending on the cause of the CS because sudden signs may be secondary to ectopic adrenocorticotropic hormone (ACTH) producing tumours, not in the pituitary gland; while insidious presentations are more common in the Cushingâs Disease (CD).
The incidence of CS, depending on pituitary, is estimated in 5 to 10 cases per million/year, predominantly in women. Patients with CS have a five-fold higher mortality, compared with the general population. The screening (performed in diabetic patients whose disease is difficult to control and who are hypertensive and obese) suggests that the prevalence may reach up to 2-5%.
Pharmacological Options in Cushingâs Syndrome: DurÃ¡n-PÃ©rez Edgar Gerardo, Moreno-Loza Oscar Tarcicio, Segovia-Palomo Antonio, Chavira-LÃ³pez Ismael Javier, Carrasco-TobÃ³n German and Lujano NicolÃ¡s Leslye Asela
Last date updated on December, 2020